The National Medical Products Administration (NMPA) of the country accepted on Feb 2 the application from CGeneTech (Suzhou) Co Ltd which, founded in SIP in 2010, hopes to put its new DPP-4 (dipeptidyl peptidase 4) inhibitor into market as soon as possible for use in treatment of type 2 diabetes mellitus.
The DPP-4 inhibitor is an oral diabetes drug which has demonstrated good efficacy and high safety in increasing insulin secretion and decreasing glucagon secretion in Phase III clinical trials.
“Yielding twice the result with half the dose, it is expected to be the best drug of its kind,” said Yu Qiao, founding CEO of the company.
It is learnt the company also has put four cancer drugs into clinical trials, of which two have passed the reviews by the US Food and Drug Administration (FDA).
February 3, 2023
